Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension

Hypertension

Volumn 48, Issue 5, 2006, Pages 965-971

  Opočenský, Martin ^a,b   Kramer, Herbert J ^c   Bäcker, Angela ^c   Vernerová, Zdenka ^a,d   Eis, Václav ^a,d   Červenka, Luděk ^a,b   Chábová, Věra Certikova ^a,d   Tesař, Vladimír ^d   Vaněčková, Ivana ^a,b  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b Ctr for Exp Cardiovasc Research   (Czech Republic)

^c UNIVERSITY OF BONN   (Germany)

^d CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Atrasentan (ABT 627), homozygous transgenic Ren 2 rats; Bosentan; End organ damage; Endothelin 1; ETA and ETB receptors; Hypertension; Survival rate

Indexed keywords

ATRASENTAN; BOSENTAN; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; DISEASE SEVERITY; HIGH SODIUM INTAKE; HOMOZYGOSITY; HYPERTENSION; MALE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; RAT; RAT STRAIN; RECEPTOR BLOCKING; SURVIVAL; SYSTOLIC BLOOD PRESSURE; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; HYPERTENSION; MALE; MICE; PODOCYTES; RATS; RATS, MUTANT STRAINS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; SURVIVAL RATE; SYSTOLE;

EID: 33750238503     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000245117.57524.d6     Document Type: Article

References (39)

1. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature (Lond). 1990;344:541-544.
2. Bachmann S, Peters J, Engler E, Ganten D, Mullins J. Transgenic rats carrying the mouse renin gene-morphological characterization of a low-renin hypertension model. Kidney Int. 1992;41:24-36.
3. Rothermund L, Kossmehl P, Neumayer HH, Paul M, Kreutz R. Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension. J Hypertens. 2003;21:2389-2397.
4. Callahan MF, Li P, Ferrario CM, Ganten D, Morris M. Salt-sensitive hypertension in (mREN-2)27 transgenic rats. Hypertension. 1996;27:573-577.
5. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (Lond). 1988;332:411-415.
6. Maguire JJ, Davenport AP. Is urotensin-II the new endothelin? Br J Pharmacol. 2002;137:579-588.
7. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis. 1989;78:225-228.
8. Mohacsi A, Magyar J, Tamas B, Nanasi PP. Effects of endothelins on cardiac and vascular cells: new therapeutic target for the future? Curr Vasc Pharmacol. 2004;2:53-63.
9. Roux S, Breu V, Ertel SI, Clozel M. Endothelin antagonism with bosentan: a review of potential applications. J Mol Med. 1999;77:364-376.
10. Moreau P, Schiffrin EL. Role of endothelins in animal models of hypertension: focus on cardiovascular protection. Can J Physiol Pharmacol. 2003;81:511-521.
11. Weinberger MH. Salt sensitivity: does it play an important role in the pathogenesis and treatment of hypertension? Curr Opin Nephrol Hypertens. 1996;5:205-208.
12. Dahl LK, Knudsen KD, Heine MA, Leitl GJ. Effects of chronic excess salt ingestion. Modification of experimental hypertension in the rat by variations in the diet. Circ Res. 1968;22:11-18.
13. Schiffrin EL. Beyond blood pressure: the endothelium and atherosclerosis progression. Am J Hypertens. 2002;15:115S-122S.
14. Vassileva I, Mountain C, Pollock DM. Functional role of ETB receptors in the renal medulla. Hypertension. 2003;41:1359-1363.
15. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev. 2003;83:253-307.
16. White KE, Bilous RW. Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients. Nephrol Dial Transplant. 2004;19:1437-1440.
17. Hayden MR, Whaley-Connell A, Sowers JR. Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: paying homage to the podocyte. Am J Nephrol. 2005;25:553-569.
18. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension. 2006;47:1084-1093.
19. Vaneckova I, Kramer HJ, Backer A, Vernerova Z, Opocensky M, Cervenka L. Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats. Hypertension. 2005;46:969-974.
20. Zicha J, Kunes J. Ontogenetic aspects of hypertension development: analysis in the rat. Physiol Rev. 1999;79:1227-1282.
21. Blezer EL, Nicolay K, Goldschmeding R, Jansen GH, Koomans HA, Rabelink TJ, Joles JA. Early-onset but not late-onset endothelin-A-receptor blockade can modulate hypertension, cerebral edema, and proteinuria in stroke-prone hypertensive rats. Hypertension. 1999;33:137-144.
22. Dvorak P, Kramer HJ, Backer A, Maly J, Kopkan L, Vaneckova I, Vernerova Z, Opocensky M, Tesar V, Bader M, Ganten D, Janda J, Cervenka L. Blockade of endothelin receptors attenuates end-organ damage in homozygous hypertensive ren-2 transgenic rats. Kidney Blood Press Res. 2004;27:248-258.
23. Mulder P, Boujedaini H, Richard V, Derumeaux G, Henry JP, Renet S, Wessale J, Opgenorth T, Thuillez C. Selective endothelin-A versus combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure. Circulation. 2000;102:491-493.
24. Opgenorth TJ, Adler AL, Calzadilla SV, Chiou WJ, Dayton BD, Dixon DB, Gehrke LJ, Hernandez L, Magnuson SR, Marsh KC, Novosad EI, von Geldern TW, Wessale JL, Winn M, Wu-Wong JR. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther. 1996;276:473-481.
25. D'Angelo G, Pollock JS, Pollock DM. Endogenous endothelin attenuates the pressor response to acute environmental stress via the ETA receptor. Am J Physiol Heart Circ Physiol. 2005;288:H1829-H1835.
26. Heller J, Hellerova S. Long-term effect on blood pressure of early brief treatment by different antihypertensive agents: a study in the prague hypertensive rat. Kidney Blood Press Res. 1998;21:445-451.
27. Saito T, Sumithran E, Glasgow EF, Atkins RC. The enhancement of aminonucleoside nephrosis by the co-administration of protamine. Kidney Int. 1987;32:691-699.
28. Gellai M, Fletcher T, Pullen M, and Nambi P. Evidence for the existence of endothelin-B receptor subtypes and their physiological roles in the rat. Am J Physiol. 1996;271:R254-R261.
29. Matsumura Y, Hashimoto N, Taira S, Kuro T, Kitano R, Ohkita M, Opgenorth TJ, Takaoka M. Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats. Hypertension. 1999;33:759-765.
30. Honore JC, Fecteau MH, Brochu I, Labonte J, Bkaily G, D'Orleans-Juste P. Concomitant antagonism of endothelial and vascular smooth muscle cell ETB receptors for endothelin induces hypertension in the hamster. Am J Physiol. 2005;289:H1258-H1264.
31. Williams JM, Pollock JS, Pollock DM. Arterial pressure response to the antioxidant tempol and ETB receptor blockade in rats on a high-salt diet. Hypertension. 2004;44:770-775.
32. Reinhart GA, Preusser LC, Burke SE, Wessale JL, Wegner CD, Opgenorth TJ, Cox BF. Hypertension induced by blockade of ET(B) receptors in conscious nonhuman primates: role of ET(A) receptors. Am J Physiol. 2002;283:H1555-H1561.
33. Barton M, d'Uscio LV, Shaw S, Meyer P, Moreau P, Luscher TF. ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension. 1998;31:499-504.
34. Ortmann J, Amann K, Brandes RP, Kretzler M, Munter K, Parekh N, Traupe T, Lange M, Lattmann T, Barton M. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension. 2004;44:974-981.
35. Rebibou JM, He CJ, Delarue F, Peraldi MN, Adida C, Rondeau E, Sraer JD. Functional endothelin 1 receptors on human glomerular podocytes and mesangial cells. Nephrol Dial Transplant. 1992;7:288-292.
36. Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, Chatziantoniou C. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol. 2003;14:1132-1144.
37. Springate JE, Feld LG, Ganten D. Renal function in hypertensive rats transgenic for mouse renin gene. Am J Physiol. 1994;266:F73-F737.
38. Macconi D, Ghilardi M, Bonassi ME, Mohamed EI, Abbate M, Colombi F, Remuzzi G, Remuzzi A. Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats. J Am Soc Nephrol. 2000;11:477-489.
39. Whitworth CE, Veniant MM, Firth JD, Cumming AD, Mullins JJ. Endothelin in the kidney in malignant phase hypertension. Hypertension. 1995;26:925-931.